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Abstract 
Ductal carcinoma in situ (DCIS) can be a precursor of invasive breast cancer. Since the advent of 
screening mammography in the 1980’s, the incidence of DCIS has increased dramatically. The value of 
screen detection and treatment of DCIS is a matter of controversy, since it is unclear to what extent 
detection and treatment of DCIS prevents invasive disease and reduces breast cancer mortality. The aim 
of this paper is to provide an overview of existing Cancer Intervention and Surveillance Modelling 
Network (CISNET) modeling approaches for the natural history of DCIS, and to compare these to other 
modeling approaches reported in the literature. Five of the six CISNET models currently include DCIS. 
Most models assume that some, but not all, lesions progress to invasive cancer. The natural history of 
DCIS cannot be directly observed and the CISNET models differ in their assumptions and in the data 
sources used to estimate the DCIS model parameters. These model differences translate into variation in 
outcomes such as the amount of overdiagnosis of DCIS with estimates ranging from 34%-72% for 
biennial screening from age 50-74 years. The other models described in the literature also report a large 
range in outcomes with, for example, progression rates varying from 20%-91%. In the future, DCIS data 
by grade from active surveillance trials, development of predictive markers of progression probability, 
and evidence from other screening modalities, such as tomosynthesis, may be utilized to inform and 
improve the models’ representation of DCIS and might lead to convergence of the model estimates. 
 
Key Words: Cancer simulation, breast cancer epidemiology, simulation models, ductal carcinoma in situ  
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Introduction 
Ductal carcinoma in situ (DCIS) represents a spectrum of abnormal cells confined to the breast duct and 
is a risk factor for invasive breast cancer development [1]. Before the introduction of mammography 
screening, DCIS was not often diagnosed. Since the advent of screening mammography in the 1980s, the 
incidence of DCIS has increased dramatically. In the United States, the incidence of DCIS increased from 
5.8 per 100,000 women in 1975 to 68.9 per 100,000 women in 2010 [2-4]. By the year 2020, more than 
one million US women are expected to be living with and have been treated for a DCIS diagnosis [1]. 
The etiology of DCIS is presumably heterogeneous and its natural history is poorly understood as 
onset, progression and regression rates are not directly observable. Some DCIS lesions likely represent a 
precursor to subsequent invasive breast cancer, but DCIS may also remain indolent for sufficiently long 
that a woman dies of other causes [5-7]. The proportion of untreated DCIS that will progress to invasive 
breast cancer is unknown [1], and therefore, the impact of detecting and treating DCIS, particularly for 
any given woman, is unclear. Treating some DCIS lesions will probably prevent invasive disease, and 
consequently might reduce breast cancer mortality, thus can be considered a benefit.  Other lesions 
might remain indolent in the absence of treatment with only harms related to their treatment 
(representing overdiagnosis and overtreatment). Since we do not know which and how many DCIS 
lesions will progress, the value of screen detection and treatment of DCIS remains unknown and is a 
matter of considerable controversy.  
Despite the uncertainty around the natural history of DCIS, some predictors for progression 
have been identified. For example, younger age at diagnosis and black ethnicity are associated with 
higher breast cancer-specific mortality among patients with DCIS [8, 9]. Other identified factors for 
progression include estrogen receptor (ER) negative status, larger DCIS tumor size, and comedonecrosis 
[9]. In addition, DCIS progression to invasive breast cancer can be predicted by cytologic grade [5, 7, 9]. 
Pathologists use three grading categories: corresponding to well (grade 1), moderately (grade 2), and 
poorly (grade 3) differentiated DCIS [10], also referred to as “low grade”, “intermediate grade”, and 
“high grade”, respectively. Grade has been found to be associated with  recurrence [11, 12] and the 
survival benefit of surgical treatment has been found to be lower for low-grade DCIS than that for 
intermediate or high-grade DCIS [13]. Furthermore, the DCIS Score, based on Oncotype DX, has been 
found to be associated with recurrence of DCIS (either as DCIS or invasive breast cancer) [14]. 
These identified prognostic factors for recurrence may enable physicians to tailor treatment 
strategies. Specifically, recommending treatment that is less aggressive would be appropriate for DCIS 
that has a low risk for future recurrence, and predictors such as age, ER status, and/or grade might be 
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used to identify low-risk lesions. Thus, understanding the natural history of DCIS and its recurrence and 
progression predictors to guide treatment strategies is important for both clinical and public health 
decisions. However, investigating the natural history of DCIS is difficult as ideal high-quality data is 
lacking, given that progression paths are not directly observable. In addition, data are also limited 
because survival for women diagnosed with DCIS is very high and a trial would need to enroll very large 
numbers of women and follow them for a lifetime to be adequately powered to detect an impact of 
screening and treatment on mortality or other endpoints. Moreover, the natural history of DCIS is 
difficult to study because the standard of care is immediate treatment following diagnosis. In these 
instances (comparative) modeling can be useful, for example to provide a range of plausible DCIS 
progression and regression rates by evaluating what set of assumptions about these rates best fit the 
existing observable data. In addition, in natural history models, the difference in risk of progression 
based on age, grade and ER status can be included by allowing varying transition rates for these factors, 
which has already been done in a well-established microsimulation model to include grade [15].   
 Furthermore, within the Cancer Intervention and Surveillance Modelling Network (CISNET) 
comparative modeling work has been done. Previously, three CISNET models estimated the amount of 
DCIS overdiagnosis in women age 74 and older. The results indicated that at older ages harms began to 
outweigh benefits, largely as a consequence of the increasing amount of overdiagnosis of DCIS at older 
ages [16], which is partly due to the higher death rate from competing causes with aging. Together, 
these modeling papers, on one hand highlight the uncertainty regarding the natural history of DCIS, but 
also show the potential value of modeling in providing information where results are consistent.  
The aim of this paper is to provide an overview of the ways CISNET models simulate the natural 
history of DCIS, illustrate how different assumptions affect results, to compare the CISNET models to 
other models described in the literature, and to highlight developments that might lead to model 
improvements or refinements.  
 
CISNET models 
CISNET DCIS models – model overview    
CISNET is a consortium of National Cancer Institute (NCI)-sponsored investigators who use statistical 
modeling to improve our understanding of cancer control interventions in prevention, screening, and 
treatment and their effects on population trends in incidence and mortality. The CISNET breast models 
have been described in detail previously and recently updated descriptions have been given [17-22]. 
Briefly, the models are designed to match breast cancer incidence and mortality rates observed in the 
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US.  Four models are micro-simulation models (models developed by Erasmus MC, University Medical 
Center Rotterdam, model E; Georgetown University Medical Center, and Albert Einstein College of 
Medicine, model G-E; MD Anderson Cancer Center, model M; and University of Wisconsin, Madison and 
Harvard Medical School, model W), one model uses an analytic approach (model developed by Dana-
Farber Cancer Institute, model D), and the remaining model is a hybrid Monte Carlo simulation (model 
developed by Stanford University, model S). The micro-simulation models include natural history 
components that approximate tumor progression in size and stage 
(https://resources.cisnet.cancer.gov/registry/site-summary/breast/). Five of the six CISNET models 
currently include DCIS (all except model S). Most models assume that some, but not all, lesions progress 
to invasive cancer, for example by including three different types of preclinical DCIS: DCIS that 
progresses to invasive disease during the preclinical phase, progressive DCIS that is diagnosed clinically, 
and DCIS that does not progress (and might regress). However, the models differ in natural history of 
DCIS (Table 1) and model structure (see Figure 1), with different pathways for the progression and 
regression of DCIS and breast cancer. For example, invasive cancer can either develop through pre-
clinical screen-detectable DCIS (Figure 1C), or also develop directly from pre-clinical DCIS that is not 
detectable at screening (Figure 1A and 1B). In the models, DCIS can regress from pre-clinical screen-
detectable DCIS to pre-clinical undetectable DCIS (Figure 1A) or to an absorbing ‘no breast cancer’ state 
and disappear (“cease to exist”) (Figure 1B and 1C). One model (model W) allows regression of pre-
clinical DCIS as well as invasive disease (Figure 1D). Although the regression of breast cancer, especially 
invasive disease, is controversial, there is some evidence supporting the possibility of regressing tumors, 
including epidemiologic evidence [23] and a case report on regression of breast on imaging [24]. 
Most of the CISNET models have used data from the Surveillance, Epidemiology, and End Results 
(SEER) Program [25], typically age-specific incidence over time, combined with data from other sources 
(Wisconsin cancer registry for model W, Dutch data for model E) to estimate DCIS parameters,  although 
one model used data from another source to develop their model (Norwegian data for model D) [26]. All 
CISNET models include a certain probability for mammography to detect DCIS at screening (Table 2). 
Specifically models D and GE use the same detection mechanism for DCIS as for invasive disease by 
including a sensitivity of screening. Model W uses  the detection probability as a function of tumor size 
and because in situ lesions are small the likelihood of detecting DCIS is lower than that for detecting 
invasive breast cancer. Model E includes two separate detection mechanisms; DCIS detection is modeled 
by including a sensitivity, whereas screen-detection of invasive disease is modeled by a threshold 
diameter. Thus, in some models the sensitivity of a screening test differs for DCIS and invasive cancer.  
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CISNET models – analysis  
The CISNET models were recently applied to evaluate screening outcomes of various screening 
strategies differing by age at which screening starts (40, 45, or 50 years) and screening interval (annual, 
biennial) for the US female population [27]. We assessed the results of those prior analyses by focusing 
on the (as yet unpublished) model-specific rates of DCIS detection and overdiagnosis of the five CISNET 
models that include DCIS [28]. Overdiagnosis was defined as the detection of tumors that would not 
have been detected in a woman’s lifetime in the absence of screening. We estimated the detection and 
overdiagnosis rate per 1000 women screened followed from age 40 over their lifetimes. In addition, the 
percentage overdiagnosis was calculated by dividing the rate of overdiagnosed DCIS by the rate of 
detected DCIS. We focus on four screening scenarios: biennial screening from 50-74 years (base), more 
frequent screening (annual screening from age 50-74 years; A50-74), an earlier starting age (biennial 
screening from age 40-74 years; B40-74), and later stopping age (biennial screening from age 50-84 
years; B50-84).  
 
CISNET models – results and implications 
For biennial screening between age 50 and 74 years, the five models that include DCIS predict that 154.4 
women (median; range across five models 137.4 – 158.5; Table 3) are diagnosed with breast cancer per 
1000 women followed from age 40 over their lifetimes. Of these women, 26.7 (25.8 – 32.3) are 
diagnosed with DCIS and 128.2 (110.7 – 131.8) with invasive disease. Of the women diagnosed with 
DCIS, 15.6 (9.0-18.8) are overdiagnosed, representing 51.3% (33.7%-71.8%) of the detected DCIS (Table 
3). In contrast, for invasive disease, the models estimate that of the 128.2 (110.7-131.8) breast cancers 
detected, 3.3 (1.8-15.4) are overdiagnosed, corresponding to 2.6% (1.5%-12.0%; Table 3). This means 
that 2.6% (1.5-12.0%) of the invasive breast cancers that are detected would not have been detected in 
the absence of screening and are overdiagnosed. There is no direct connection between the amount of  
overdiagnosis of DCIS and overdiagnosis of invasive disease in the models. For example, one model 
predicts relatively low overdiagnosis percentages for DCIS as well as invasive breast cancer (model GE), 
whereas another model predicts relatively high percentages for both (model M). In contrast, there are 
also models that have modest estimates of DCIS overdiagnosis combined with relatively high estimates 
of invasive disease overdiagnosis (model W) or the other way around (model E). 
When annual screening from age 50-74 years is simulated, the models estimate 0.1-14.0 
additional cases of DCIS being detected of which 0.1-13.7 are overdiagnosed (Table 4). Also, the models 
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differ for the source for additional DCIS cases. For Models D, M, the increase in detection of DCIS is 
entirely overdiagnosis, whereas in models E, GE, W it is combination of overdiagnosis and earlier 
detection of lesions with progressive potential.    
In addition, the order of scenarios that have the largest increase in overdiagnosis of DCIS varies 
across models, as well as the magnitude of the increase. For example, for annual screening the increase 
in overdiagnosis varies between 0.1 and 13.7 overdiagnosed DCIS cases across models. Some models 
estimate the largest change in detection and overdiagnosis when annual screening is considered 
(models E, M, W), whereas other models predict the largest increase when upper age of screening is 
extended to age 84 (models D and GE).  
  For the biennial screening scenario from age 50-74 years, the highest percentage of 
overdiagnosis of DCIS and invasive breast cancer was estimated by model M followed by W. This can be 
explained by the modeling choice of model M to assume a rather stable trend in breast cancer incidence 
(background trend) over time and, therefore, assign more of the increase to overdiagnosis than other 
CISNET models. Model W assumes that some invasive disease is non-progressive, and consequently, has 
a higher estimate for overdiagnosis than the other three models, especially for invasive disease.  
 For the other scenarios, annual screening from age 50-74 years, biennial screening from age 40-
74 years, and biennial screening from age 50-84 years, there are two clusters of models: models D and 
M assign the increase in detection of DCIS when screening more intensively entirely to overdiagnosis. 
For model M that is again related to the stable background trend and for model D, the screen detectable 
period for DCIS is relatively short. The other three models (models E, GE, and W) only assign a 
proportion of the increase to overdiagnosis and a proportion to earlier diagnosis. Models E and GE 
assign most of the increase to overdiagnosis when moving to older ages and a smaller percentage when 
moving to younger ages.   
 
Literature 
Description of other DCIS models in the literature  
To  improve the understanding of the natural history of DCIS, we conducted a literature search to 
identify DCIS models that have been described in the literature. We searched PubMed and JSTOR for 
“DCIS natural history modeling” and “DCIS progression”, and selected the articles that focus on the 
estimation of key DCIS natural history parameters, such as mean sojourn time for screen-detectable pre-
clinical DCIS, and percent of DCIS cases that progress to either invasive cancer, clinical DCIS, or 
potentially regress.  We identified 10 relevant studies, of which nine include DCIS natural history 
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modeling (Table 5). Among them, four studies use Markov models [29-32] and five use simulation 
models [15, 33-36], with parameters estimated with either maximum likelihood, Bayesian Gibbs 
sampling or least square methods, and varying assumptions about DCIS natural history pathways. Seven 
studies assumed that all invasive breast cancers progress through a pre-clinical in situ or DCIS state that 
can be detected at screening [15, 29, 32-34, 36], whereas the other two studies assumed that some DCIS 
or in situ lesions first become visible on mammograms as small invasive tumors [30, 35]. DCIS or in situ is 
assumed to have both progressive and non-progressive paths in eight studies [15, 29-34, 36], with one 
study also including non-progressive invasive cancers [36].  
These 10 studies used various data sources including different combinations of: i) data 
aggregated from population registries [15, 30, 35, 36], ii) observed national screening service program 
data [32, 33, 37], iii) detailed data from randomized screening trials [29, 31, 32, 34] and iv) estimates 
made from previously reported studies including studies of DCIS first overlooked at mammography [30, 
36]. Generally, more detailed screening data makes it possible to deduce more realistic natural history 
models, fitting the model using data from different screening rounds and screening histories [29, 32]. In 
addition to the different data sources, three studies include all in situ lesions [29, 31, 36], while seven 
others only include DCIS [15, 30, 32-35, 37].  
 
Parameters in the literature useful for DCIS modeling 
The estimated proportion of DCIS progressing to invasive cancer varies widely in the literature (Table 5), 
mainly due to the available data, study-specific model assumptions, and different model structures. 
When all invasive breast cancer is assumed to go through a pre-clinical screen detectable DCIS state, the 
estimated progression rate of DCIS to invasive varies from 61% to 91% [15, 29, 31-34, 36]. When this 
assumption is not made, the estimated progression rate from DCIS to invasive varies from 20% to 24.4% 
[30, 35].  Some studies report a large proportion of progressive DCIS [31, 33, 34, 36], while other studies 
report that most DCIS cases do not progress to invasive cancer [30, 35]. When the proportion of 
progressive DCIS is reported by screening round, the subsequent screening rounds often reported 
smaller proportions of progressive DCIS [29, 32] compared to initial screening, as cases with a long 
sojourn time were diagnosed in earlier screening exams. High-grade DCIS cases have a larger proportion 
progressing to invasive than low-grade DCIS cases [15].   
 As for the mean sojourn time, when all invasive cancer are assumed to be screen detectable at a 
pre-clinical DCIS stage, the estimated mean sojourn time for progressive DCIS cases in the pre-clinical 
screen-detectable DCIS state are usually short varying from 1 month to 5 years [29, 31, 32, 34, 35]. On 
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the other hand, the sojourn time estimates are much longer if it is assumed that only a small fraction of 
invasive cancers comes from pre-clinical screen-detectable DCIS [30]. The estimated mean sojourn time 
in pre-clinical screen-detectable DCIS state for DCIS cases that progress to clinical DCIS or regress is in 
typically longer than the mean sojourn time of DCIS cases that progress to invasive cancer [29, 32].   
The mammography sensitivity for DCIS varies from 40% to 99% [29, 31, 33, 34]. The mean 
sojourn time for progressive DCIS in the pre-clinical screen detectable DCIS state tends to be smaller 
when mammography sensitivity is high. These variations reveal the uncertainty regarding the natural 
history of DCIS, highlighting the need and potential directions of CISNET modeling. 
 
Discussion 
While the CISNET models have generated relatively similar results and conclusions in most other 
respects, DCIS detection rates and overdiagnosis reveal more variation in results, with predicted DCIS 
incidence ranging from 25.8 – 32.3 per 1000 women age 40 followed over their lifetimes, and estimates 
of DCIS overdiagnosis ranging from 34%-72% for biennial screening from age 50 to 74 years. The large 
difference in the predicted amount of overdiagnosis of DCIS between models likely reflects the 
continued uncertainty about DCIS natural history, in particular the progression rates, which is also 
reflected in the results from other models described in the literature with reported progression rates 
varying from 20% to 91%. 
In the literature outside of CISNET, several approaches have been proposed to model DCIS. The 
variations in model structure, assumptions and results make it challenging to deduce good overall 
estimates of key natural history parameters. Given the uncertainties in the DCIS models, a realistic 
approach to DCIS modeling is to adopt several plausible sets of model parameters and to evaluate a 
range of outcomes generated from the models. The CISNET models are well-suited for this type of 
analysis. CISNET models have the ability to project long-term implications for DCIS assumptions in terms 
of breast cancer outcomes such as life expectancy and overdiagnosis, and can thus assess how much 
early detection impacts breast cancer mortality. Also, moving forward, CISNET models are capable of 
utilizing multiple models and vary model parameters, to explore the impact of different DCIS 
assumptions on outcomes more systematically. In addition, both the impact of screening and treatment 
on DCIS-related outcomes can be systematically reviewed and compared. Although it remains to be seen 
to what extent these analyses will provide sufficiently accurate and consistent findings to inform clinical 
practice, the comparative modeling effort of the CISNET models will likely contribute to a greater 
understanding of DCIS.  
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Despite the large difference in the predicted amount of overdiagnosis of DCIS between models, 
all models indicated that the amount of overdiagnosis of DCIS is substantial (i.e., 34%-72% for biennial 
screening from age 50-74 years), indicating that per 1000 women followed over their lifetimes 9-19 are 
overdiagnosed with DCIS and the majority of those women will undergo treatment for their non-invasive 
disease. Almost all women (98%) diagnosed with DCIS undergo a surgical procedure [13, 38] and recent 
work found an increase in the utilization of mastectomy with reconstruction and contralateral risk-
reducing mastectomy over time [39]. There was also an increase in the proportion of women 
undergoing adjuvant radiation therapy after surgery from 58.5% in 1998-1999 to 70% during 2006-2011 
[39]. 
Modeling estimates might improve and results might converge when new data becomes 
available. A unique opportunity to improve DCIS natural history modeling comes from trials on active 
surveillance. Several trials are currently underway to evaluate active surveillance approaches for DCIS. In 
the UK, the Low Risk DCIS Trial (LORIS), is comparing surgical excision to active surveillance without 
excision [40, 41]. Similarly, the European Organisation for Research and Treatment of Cancer (EORTC) 
has started a trial on the management of low-risk DCIS (LORD), which is a randomized, multicenter, non-
inferiority trial, between standard therapy approach versus active surveillance [42]. In the US a 
prospective, randomized trial, Comparing Operative to Medical Endocrine Therapy for low-risk DCIS 
(COMET), has recently been funded. Women diagnosed with low-risk DCIS will be randomized to receive 
either guideline-concordant care of surgical intervention, with or without radiation, or active 
surveillance of a mammogram every 6 months for 5 years. Patients in both trial arms are free to choose 
endocrine therapy. Also, in the US, several research networks, called cooperative groups, that conduct 
cancer clinical research primarily under the sponsorship of the NCI, are presently testing the use of neo-
adjuvant hormonal therapy in postmenopausal women with ER-positive DCIS prior to surgery; those 
with a complete response based on magnetic resonance imaging (MRI) will not receive additional 
therapy. However, it will take a long time before results are available, e.g., for LORIS initial results are 
expected in 2020 and for LORD the results are not expected before 2029. When they do become 
available these data present a unique opportunity to validate models by comparing the model 
projections to the final trial data. 
In the meantime, thus, before final results from these trials become available, the models can 
be used to evaluate which assumptions affect outcomes most. Also, data from several different sources 
might be used and combined to compare model outcomes and see what model structure and 
progression rates fit the data best. For example, data from different screening modalities can inform 
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models, as the ability to detect DCIS varies across modalities. Screening ultrasound is less likely to detect 
DCIS compared to mammography in the small number of controlled experiments available that make 
this comparison, because ultrasound is unlikely to detect micro-calcifications. MRI may be more 
sensitive than mammography [43, 44] by detecting the pathophysiologic properties like basement 
membrane permeability in DCIS [45] perhaps explaining the tendency of MRI to detect intermediate and 
high grade DCIS more readily than mammography. By using a particular set of parameters and modelling 
different screening modalities, it might become possible to narrow down the range of plausible 
progression parameters. Furthermore, data by ER and grade might be used to refine the models. 
Subsequently, the updated and refined models can be used to simulate active surveillance strategies 
and quantify the predicted outcomes for subgroups of women varying by age and with DCIS varying by 
grade and ER status. Until then, the model results consistently show a considerable amount of 
overdiagnosis of DCIS, which increases with more frequent screening. This indicates that women 
undergoing regular screening with a screen-detected DCIS are quite likely to be overdiagnosed. Thus, 
given the substantial amount of overdiagnosis estimated by the CISNET models for DCIS in general, the 
model results support the safety and value of observational trials for low-risk DCIS.  
 
Conclusion 
Five of the six CISNET models currently include DCIS with most models assuming that some, but not all, 
DCIS lesions progress to invasive cancer. The models differ in natural history of DCIS and model 
structure, with different pathways for the progression and regression of DCIS and breast cancer. 
Although the predicted amount of overdiagnosis of DCIS varied substantially across CISNET models, all 
models indicated that the amount of overdiagnosis of DCIS is substantial, ranging from 34%-72% for 
biennial screening from age 50 to 74 years. This large range in estimates reflects that the natural history 
of DCIS is still not very well understood. In the future, models can be refined, for example, by using data 
on DCIS by grade and ER status, and, subsequently, outcomes of active surveillance strategies can be 
simulated. Ultimately, these results can then be used to inform women diagnosed with DCIS, and, 
through shared decision making, their outcomes can be improved by ensuring that treatment is aligned 
with their preferences.   
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Table 1. Natural history of DCIS in the CISNET models.  
Model in situ or DCIS?* Do all tumors start as in situ? Progression/regression Model structure 
D DCIS only        
Yes, but some DCIS is not screen-
detectable and assumed to progress 
to invasive directly  
DCIS progress to clinical DCIS or invasive breast 
cancer at exponential rates with mean sojourn 
time of 1.5-3 years; DCIS may also go back to a 
state in which it is undetectable [19] 
Figure 1A 
E All in situ  Yes 
DCIS progress to clinical or invasive breast cancer 
at an exponential rate with age and calendar year 
dependent sojourn times; DCIS may also regress 
[22] 
Figure 1B 
GE DCIS only Yes 
DCIS progress to clinical or invasive breast cancer 
at an exponential rate with mean sojourn time of 
2.97 years; DCIS may also regress [21] 
Figure 1C 
M 
 
Model M is not a natural history model. It does not specify how tumors grow. It is an empirical model to describe screening, incidence, treatment and 
mortality. Under different screening scenarios, different stage distribution tables obtained from observed data [28] are used to assign tumor stages: 
DCIS, stages I, II, III or IV. DCIS patients are assumed to have the same survival as normal population, given age and birth year, no matter what 
treatments they receive.[18] 
 
W 
All in situ. Model W also 
separated in situ into DCIS 
and non-DCIS in situ 
Yes 
All tumors, including DCIS, progress according to a 
Gompertz-type growth function, where the 
growth parameter is a random variable 
distributed with Gamma. Small size defines in 
situ. All tumors grow until they reach a maximum 
size. All tumors progress although a subset with 
"limited malignant potential" (LMP) stop at early 
invasive. LMPs comprise approximately 30-50% of 
all onset tumors [17] 
Figure 1D 
17 
 
Model D: Dana-Farber Cancer Institute, Boston, Massachusetts. Model E: Erasmus MC, University Medical Center Rotterdam, Rotterdam, the 
Netherlands. Model GE: Georgetown University Medical Center, Washington, DC, and Albert Einstein College of Medicine, Bronx, New York. 
Model M: MD Anderson Cancer Center, Houston, Texas. Model W: University of Wisconsin, Madison, Wisconsin, and Harvard Medical School, 
Boston, Massachusetts. 
* in situ: DCIS and lobular carcinoma in situ (LCIS)   
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Table 2. Detection mechanism of DCIS in the CISNET models. 
Model Clinical detection mechanism Screen detection mechanism Detection mechanism DCIS vs. invasive cancer   
D 
Some DCIS progress to clinical DCIS with symptoms - 
this rate matches age-specific incidence rate of DCIS in 
pre-screening era 
Sensitivity varying by screening 
modality, age, calendar year 
Same mechanism for DCIS and invasive cancer by test 
sensitivity 
E 
Some DCIS progress to clinical DCIS with symptoms - 
this rate matches age-specific incidence rate of DCIS in 
pre-screening era 
Sensitivity varying by calendar 
year 
DCIS is detected by test sensitivity; invasive disease is 
detected using a threshold diameter  
GE 
Progressive DCIS are clinically detected the same as 
more advanced lesions. Non-progressive DCIS are 
NEVER clinically detected. 
Sensitivity varying by screening 
modality, age, calendar year 
Same mechanism for DCIS and invasive cancer by test 
sensitivity  
M  Model M makes no explicit mechanism assumptions regarding DCIS detection.  
W 
Some DCIS are clinically diagnosed similarly as more 
advanced lesions. Clinical detection probability is an 
increasing function of tumor size  and varies by  age 
and calendar year. Clinical detection probabilities are 
in general smaller than screen detection probabilities; 
therefore a tumor is less likely to be detected via 
clinical surfacing than by screening.   
Sensitivity varying by is tumor 
size, age, calendar year 
Detection probability is an increasing function of tumor 
size, thus because in situ are small by definition, 
likelihood of detection of DCIS is less than that for 
invasive cancer 
 
Model D: Dana-Farber Cancer Institute, Boston, Massachusetts. Model E: Erasmus MC, University Medical Center Rotterdam, Rotterdam, the 
Netherlands. Model GE: Georgetown University Medical Center, Washington, DC, and Albert Einstein College of Medicine, Bronx, New York. 
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Model M: MD Anderson Cancer Center, Houston, Texas. Model W: University of Wisconsin-Madison, Madison, Wisconsin, and Harvard Medical 
School, Boston, Massachusetts.  
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Table 3. Detection and overdiagnosis of DCIS and invasive disease across the CISNET models for biennial screening from age 50-74 years. 
 
Model 
DCIS dx 
per 1000 
DCIS overdx 
per 1000 
%overdx 
DCIS 
invasive dx 
per 1000 
invasive overdx 
per 1000 
%overdx 
invasive 
total dx per 
1000 
overdx per 
1000 
%overdx 
(DCIS + 
invasive) 
D 30.2 15.5 51.3% 128.3 3.3 2.6% 158.5 18.8 11.9% 
E 25.8 16.1 62.4% 131.8 2.0 1.5% 157.6 18.1 11.5% 
GE 26.7 9.0 33.7% 110.7 1.8 1.6% 137.4 10.8 7.9% 
M 26.2 18.8 71.8% 128.2 15.4 12.0% 154.4 34.2 22.2% 
W 32.3 15.6 48.3% 114.8 9.9 8.6% 147.1 25.5 17.3% 
Median 26.7 15.6 51.3% 128.2 3.3 2.6% 154.4 18.8 11.9% 
Model D: Dana-Farber Cancer Institute, Boston, Massachusetts. Model E: Erasmus MC, University Medical Center Rotterdam, Rotterdam, the 
Netherlands. Model GE: Georgetown University Medical Center, Washington, DC, and Albert Einstein College of Medicine, Bronx, New York. 
Model M: MD Anderson Cancer Center, Houston, Texas. Model W: University of Wisconsin-Madison, Madison, Wisconsin, and Harvard Medical 
School, Boston, Massachusetts. 
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Table 4. Changes in DCIS detection and overdiagnosis of DCIS when moving from biennial 50-74 years to other screening scenarios.  
 
change in  DCIS detection change  in DCIS overdiagnosis 
change in DCIS overdx   
change in DCIS detection 
Model A50-74 B40-74 B50-84 A50-74 B40-74 B50-84 A50-74 B40-74 B50-84 
D 0.1 0.0 2.8 0.1 0.1 2.8 100% N/A 100% 
E 8.5 4.8 5.6 6.7 3.3 5.2 79% 69% 93% 
GE 3.2 3.6 6.3 0.4 1.2 3.0 13% 33% 48% 
M 13.6 5.0 5.5 13.7 5.1 5.6 101% 102% 102% 
W 14.0 2.4 9.7 7.1 1.5 -1.1 51% 63% -11% 
A50-74: annual screening from age 50-74 years. 
B40-74: biennial screening from age 40-74 years. 
B50-84: biennial screening from age 50-84 years.  
Model D: Dana-Farber Cancer Institute, Boston, Massachusetts. Model E: Erasmus MC, University Medical Center Rotterdam, Rotterdam, the 
Netherlands. Model GE: Georgetown University Medical Center, Washington, DC, and Albert Einstein College of Medicine, Bronx, New York. 
Model M: MD Anderson Cancer Center, Houston, Texas. Model W: University of Wisconsin-Madison, Madison, Wisconsin, and Harvard Medical 
School, Boston, Massachusetts. 
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Table 5. Overview of studies on modeling DCIS. 
1st Author (Year), 
Journal Paper title 
Approaches/Models 
for DCIS natural history Data sources Natural History assumptions 
Yen (2003), Eur J 
Cancer. [32] 
Quantifying the potential problem of 
overdiagnosis of ductal carcinoma in situ in 
breast cancer screening 
Markov model 
Swedish two county trial, service 
screening programs from UK, US 
Netherlands, and Australia 
Healthy cases can progress to pre-clinical screen 
detectable progressive or non-progressive DCIS; 
progressive DCIS progress to invasive breast cancer; 
non-progressive DCIS regress to a separate state 
where no tumor is apparent. 
Ozanne (2011), 
Breast Cancer Res 
Treat. [35] 
Characterizing the impact of 25 years of 
DCIS treatment Simulation model US SEER (1975-2005) incidence 
The percentage of the DCIS lesions that are assumed 
to progress to invasive breast cancer varies between 
0% and 100%. The initial assumption that DCIS is a 
short-term obligate precursor of invasive cancer 
must be reevaluated based on the results. 
de Gelder (2011), 
Epi Rev. [33] 
Interpreting overdiagnosis estimates in 
population-based mammography 
screening 
Simulation model Dutch population data from public screening program 
Healthy cases can progress to pre-clinical screen 
detectable DCIS or invasive breast cancers; pre-
clinical screen detectable DCIS can regress, progress 
to clinical DCIS, or progress to invasive breast cancer. 
Gunsoy (2012), 
Breast Cancer 
Res. [29] 
Modeling the overdiagnosis of breast 
cancer due to mammography screening in 
women aged 40-49 in the United Kingdom 
Markov model UK Age trial  
Healthy cases can progress to pre-clinical screen 
detectable progressive in-situ or non-progressive in-
situ; progressive in situ progress to invasive breast 
cancers 
Tan (2013), Br J 
Cancer. [31] 
Quantifying the natural history of breast 
cancer 
Markov model 
(Bayesian) Swedish randomized trials 
Healthy cases can progress to pre-clinical screen 
detectable progressive DCIS or non-progressive DCIS; 
progressive DCIS progress to invasive breast cancer. 
Ryser  (2016), J 
Natl Cancer Inst. 
[30] 
Outcomes of Active Surveillance for DCIS: A 
Computational Risk Analysis   Markov model 
US SEER (1999-2011) for 
cumulative mortality estimates 
and natural history model 
summarized from a variety of 
studies  
Healthy cases can progress to the pre-clinical screen 
detectable progressive DCIS or non-progressive DCIS; 
progressive DCIS progress to localized invasive breast 
cancer. 
Duffy (2016), 
Lancet Oncol. 
[37] 
Screen detection of ductal carcinoma in 
situ and subsequent incidence of invasive 
interval breast cancers: a retrospective 
population-based study 
Poisson regression UK National Health Service Breast Screening Program (NHSBSP) Not specified.  
de Koning (2006), 
Breast Cancer 
Res. [34] 
Overdiagnosis and overtreatment of breast 
cancer: microsimulation modelling 
estimates based on observed screen and 
clinical data 
Simulation model Dutch pilot studies in Utrecht & Nijmegen; EORTC 
Healthy cases can progress to pre-clinical screen 
detectable DCIS; pre-clinical screen detectable DCIS 
cases can progress to clinical DCIS or invasive breast 
cancer. 
Seigneurin 
(2011), BMJ. [36] 
Overdiagnosis from non-progressive cancer 
detected by screening mammography: 
stochastic simulation study with calibration 
to population based registry data 
Simulation model 
(Bayesian) 
Isere, France incidence rates of 
breast cancer and DCIS (1991-
2006) with some screening 
information  
Healthy cases can progress to in situ; in situ cases 
can be non-progressive, progressive to clinical, and 
progressive to invasive; invasive cancer can also be 
non-progressive or progressive. 
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van Luijt (2016), 
Breast Cancer 
Res. [15] 
The distribution of ductal carcinoma in situ 
(DCIS) grade in 4232 women and its impact 
on overdiagnosis in breast cancer 
screening 
Simulation model  
Nationwide network and registry 
of histopathology and 
cytopathology in the Netherlands 
(PALGA) data 
Healthy cases can progress to different grades of 
DCIS; lower grade DCIS can progress to higher grade 
DCIS and vice versa; each grade of DCIS can progress 
to invasive cancer that are charaterized by tumor 
stage. 
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1st Author (Year), 
Journal 
All invasive cancers progress 
through screening detectable 
DCIS? 
Screening detectable 
DCIS might regress to a 
non-detectable stage 
Regression  Progression Mean sojourn time 
Mammography 
sensitivities to 
detect DCIS/in 
situ 
Yen (2003), Eur J 
Cancer. [32] Yes Yes 
37% (19%-46%) at 1st 
screening; 4% (3%-21%) 
at 2nd screening 
To invasive: 100-%non-
progression 
for non-progression: 30y (6y-
37y), for progression to 
invasive: 3mo (2mo-5mo) 
Not specified 
Ozanne (2011), 
Breast Cancer Res 
Treat. [35] 
No Not specified Not specified 
To invasive: 20% of 
progression rate matches 
SEER data best 
Not specified Not specified 
de Gelder (2011), 
Epi Rev. [33] Yes Yes 11% of DCIS regress 
To clinical DCIS: 28% ;  
To invasive: 61%  2.6y  for DCIS: 72%  
Gunsoy (2012), 
Breast Cancer 
Res. [29] 
Yes No  Not specified 
To invasive: 45% (95%CI: 
23%-75%) at 1st screen, 
60% (95%CI: 40%-78%) at 
incidence screen 
for pre-clinical non-progressive 
DCIS to clinical DCIS: 1.3y 
(95%CI: 0.4y-3.4y), for pre-
clinical progressive DCIS: 0.11y 
(95%CI: 0.05y-0.19y).  
for in situ: 82% 
(95%CI: 43%-99%)  
Tan (2013), Br J 
Cancer. [31] Yes Yes Not specified 
91%(95%CI: 85%-97%) 
aggressive  
for aggressive DCIS to invasive 
0.5mo (95%CI: 0-1mo) 
for DCIS: 88% 
(95%CI: 83%-92%) 
Ryser  (2016), J 
Natl Cancer Inst. 
[30] 
No Yes Not specified 24.4% (11.3%-67%) 
for progressive DCIS to 
localized invasive (did not 
specify whether to pre-clinical 
or clinical invasive): 9.8y (6.4y-
13.5y)  
for MRI: 84% 
(77%-100%); for 
mammography: 
40% (33%-50%) 
Duffy (2016), 
Lancet Oncol. 
[37] 
Not specified Not specified Not specified 
1 invasive interval cancer 
case is estimated to be 
avoided per 5 DCIS cases 
Not quantified, but short Not specified 
de Koning (2006), 
Breast Cancer 
Res. [34] 
No Yes Not specified To either invasive or clinical : 90%  
Dutch pilot study suggests 2.8y with 99% sensitivity. 
Nijmegen data suggests 2.5y. EORTC trial suggests 5y 
with 40% sensitivity.   
Seigneurin 
(2011), BMJ. [36] Yes Yes 
6% non-progressive in 
situ (95%CI 0%--17%) 
To invasive: 91% (95%CI: 
84%-97%)  Not specified Not specified 
van Luijt (2016), 
Breast Cancer 
Res. [15] 
Yes Yes 
4% low, 2% 
intermediate, and 1% 
for high grade DCIS 
To invasive: 16% low, 
31% intermediate, 53% 
for high grade DCIS 
Not specified Not specified 
Note: ranges present values estimated from different studies or data sources unless otherwise specified.  
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Figure 1A. Model D 
 
Normal Tissue Pre-clinical undetectable DCIS
Pre-clinical Screen-
detectable DCIS
Clinical DCIS with 
symptoms
Clinical IBC With 
Symptoms
Breast Cancer Death
No Breast Cancer
Pre-clinical IBC
   
Figure 1B. Model E 
Normal Tissue Pre-clinical undetectable DCIS
Pre-clinical Screen-
detectable DCIS
Clinical DCIS with 
symptoms
Clinical IBC With 
Symptoms
Breast Cancer Death
Pre-clinical Screen-
detectable IBC
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Figure 1C. Model GE 
Normal Tissue Pre-clinical Screen-detectable DCIS
Clinical DCIS with 
symptoms
Clinical IBC With 
Symptoms
Breast Cancer Death
Pre-clinical Screen-
detectable IBC
       
Figure 1D. Model W  
Figure 1. Schematic overview of models for the natural history of DCIS and invasive breast cancer. 
Invasive cancer can either develop through pre-clinical screening detectable DCIS (Figure 1C), or also 
develop directly from pre-clinical DCIS not detectable at screening (Figure 1A, 1B and 1D). Models 
include progression from preclinical screen-detectable DCIS to either clinical DCIS or preclinical invasive 
disease (Figure 1A, 1B, 1C, 1D), regression from preclinical DCIS to normal tissue (Figure 1D), to pre-
clinical undetectable DCIS (Figure 1A), or to a ‘no breast cancer’ (absorbing) state in which women are 
no longer at risk for developing DCIS or invasive breast cancer (Figure 1B and 1C). Regression from 
invasive disease is also possible (Figure 1D).  
Normal Tissue Pre-clinical Screen-detectable DCIS
Clinical DCIS with 
symptoms
Clinical IBC With 
Symptoms
Breast Cancer Death
Pre-clinical Screen-
detectable IBC
No Breast Cancer
 
